Dr. Twishi Gulati, Phenomics Australia’s National Service Coordinator, and Dr. John Parisot, our Strategic Partnerships Advisor, had the privilege of visiting a prominent research hub in Adelaide. Located at Phenomics Australia nodes within the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide, our highly proficient team demonstrated cutting-edge technology and revolutionary breakthroughs.
We deeply appreciate the chance to observe the groundbreaking advancements in Precision Medicine research and beyond taking place within our nodes and are excited to share this journey with our network.
The immersive tour commenced under the guidance of Phenomics Australia’s expert team from the South Australian Genome Editing Facility (SAGE). Participants were treated to an up-close view of state-of-the-art laboratories and the latest In Vivo genome engineering and disease modelling advancements, offering insight into the solutions they provide for researchers. Specifically, they showcased their expertise in cutting-edge genome editing technology, such as CRISPR, used to create in vivo disease models across various fields of research.
They also had the fantastic opportunity to tour the Functional Genomics South Australia (FGSA) facility at the University of Adelaide where their expert team revealed advanced facilities featuring state-of-the-art technology and instrumentation, including automated whole genome CRISPR screening.
Our sincere thanks to Ms Melissa White Manager of SAGE’s facility, and Ms Sandra Piltz SAGE’s Transgenic Coordinator and to Prof. Simon Barry, Phenomics Australia Scientific Director and head of the FGSA facility and Dr Jason Gummow manager of FGSA for their dedication and passion, making this visit an unforgettable experience.
We’re excited about the innovative work happening at Phenomics Australia nodes and can’t wait to share their advancements and achievements with our community.
Get in contact to explore the expertise and services provided by SAGE and FGSA.
Phenomics Australia provides a national centre of expertise and service provision to deploy a more comprehensive and sophisticated range of in vitro Genome Engineering and Disease Modelling capabilities to understand the functional consequences of DNA sequence variation in the human genome for health and disease while maintaining the expertise for in vivo disease modelling and genome engineering. To meet the high demand for adaptable and scalable disease-modelling platforms for improved diagnosis, Precision Medicine for genetic disorders, and therapeutic development by both academia and the biopharmaceutical industry, Phenomics Australia offers In Vitro services through a collaborative consortium of ten laboratories and facilities across Australia, operating at ANU (ANU Centre for Therapeutic Discovery), Perkins (Translational Cancer Research Program in Oncology), Monash (Monash Organoid Program & Monash Genome Modification Platform), MCRI (iPSC derivation & Gene Editing Facility), Peter Mac (Victorian Centre for Functional Genomics), UMelb (Centre for Stem Cell Systems & Stem Cell Disease Modelling Laboratory), UQ (In vitro Genome Engineering and Disease Modelling Service), and VCCRI (Stem Cell Production Facility iPSC Reprogramming Service)
Through the Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre, the Harry Perkins Institute of Medical Research (Perkins), the ANU Centre for Therapeutic Discovery (ACTD, The John Curtin School of Medical Research, ANU) the Monash Functional Genomics Platform (MFGP) at Monash University, and the Functional Genomics South Australia (FGSA) at the University of Adelaide (in partnership with SAHMRI), Phenomics Australia Functional Genomics and High-throughput screening services enable biomedical researchers Australia-wide with the ability to perform novel discovery-based screens using multiple platforms.
